Pooled NHANES data from 2005-2023 show cardiovascular-kidney-metabolic syndrome costs US adults 20.0 million DALYs annually. Stages 3-4, holding just 15.8% of adults, generate 76% of attributable years of life lost, and stage 4 alone accounts for 65% of years lived with disability. Mortality hazard climbs from 1.39 at stage 2 to 3.22 at stage 4, while stage 1 matches stage 0 (HR 0.99). Stage 0 prevalence fell 2.3% yearly from 2006 to 2016 as stage 1 rose 3.1%. Smoking and inactivity explain 30.5% of burden.
The real insight is the mismatch between where risk accumulates and where harm registers. Stage 1 (excess adiposity or dysfunctional fat) looks harmless in mortality terms today, but it is the pipeline feeding later stages, and the 2005-2023 trend suggests the pipeline is widening. For individuals, this argues against complacency about modest weight gain, borderline glucose, or blood pressure drift: normal near-term mortality does not mean low long-term trajectory. The 30.5% attributable to smoking and inactivity reinforces that modifiable behaviours remain large levers. Caveats are substantial: NHANES is cross-sectional, stage assignment relies on single measurements, mortality linkage ends in 2018, and the prevalence-trend and attribution models rest on assumptions that cannot establish causation. The DALY-bias critique is a methodological argument for resource prioritisation, which sits outside what a reader can act on directly. This is a preprint and has not been peer reviewed, so estimates may shift. Overall the work is incremental and confirmatory on late-stage burden, with a thought-provoking framing on prevention timing.